J Control Release:两亲性磷脂肽树状大分子纳米载体用于前列腺癌siRNA治疗

2020-04-10 AlexYang MedSci原创

RNA干扰(RNAi)具有巨大的治疗应用前景。然而,安全和成功的临床转化需要进一步的发展高效的传输系统。

RNA干扰(RNAi)具有巨大的治疗应用前景。然而,安全和成功的临床转化需要进一步的发展高效的传输系统。

最近,有研究人员报道了两亲性磷脂肽树状大分子(AmPPDs)可以介导靶向Hsp27的siRNA的高效传递来治疗去势抵抗性前列腺癌(CRPC)。AmPPDs以天然脂质衍生物DSPE为疏水性尾部,不同树状的L-赖氨酸为亲水头,能够将siRNA压缩进入纳米颗粒,从而保护其免受酶的降解。有趣的是,DSPE-KK2,AmPPD携带更小的亲水性树突,能够促进细胞内更有效地吸收和核内体释放所形成的siRNA复合物,同时具有更好的siRNA释放能力,最终在体外和体内产生更强的基因沉默和抗癌作用。DSPE-KK2在siRNA传输中的出色表现可能归因于疏水尾部和亲水树突部分的最优平衡。

最后,研究人员指出,他们的发现为开发安全和有效的基于树状大分子的siRNA传输系统提供了指导,为抗击各种疾病带来希望。

原始出处:

Dong Y, Chen Y, Zhu D et al. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy. J Control Release. 02 Apri 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2075759, encodeId=9a3c20e575976, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Feb 22 10:12:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645481, encodeId=d5121645481f2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 13 15:12:46 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548205, encodeId=9180154820557, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 12 04:12:46 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040709, encodeId=bd1f1040e095a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Apr 10 16:12:46 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2075759, encodeId=9a3c20e575976, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Feb 22 10:12:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645481, encodeId=d5121645481f2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 13 15:12:46 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548205, encodeId=9180154820557, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 12 04:12:46 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040709, encodeId=bd1f1040e095a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Apr 10 16:12:46 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2021-02-13 mei539
  3. [GetPortalCommentsPageByObjectIdResponse(id=2075759, encodeId=9a3c20e575976, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Feb 22 10:12:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645481, encodeId=d5121645481f2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 13 15:12:46 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548205, encodeId=9180154820557, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 12 04:12:46 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040709, encodeId=bd1f1040e095a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Apr 10 16:12:46 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2075759, encodeId=9a3c20e575976, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Feb 22 10:12:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645481, encodeId=d5121645481f2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Feb 13 15:12:46 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548205, encodeId=9180154820557, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Sun Apr 12 04:12:46 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040709, encodeId=bd1f1040e095a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Apr 10 16:12:46 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2020-04-10 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Sci Transl Med: 转移性前列腺癌新突破:免疫检查点抑制剂彰显成效!

德克萨斯大学安德森癌症中心进行的伊匹单抗Ⅱ期临床试验中,研究人员在一组患者的肿瘤中发现了存在活性T细胞反应的预处理证据,在接受伊匹单抗治疗后,患者的生存期明显延长。

Oncogene:毒蕈碱受体能够促进前列腺癌的去势抵抗性生长

前列腺癌(PCa)神经支配能够导致PCa的恶化。然而,神经支配对PCa细胞的精细影响仍旧了解很少。

Oncogene:p300/CBP抑制剂能够增强前列腺中程序性死亡配体1阻断治疗的效果

抗体药物的程序性死亡配体1(PD-L1)阻断在癌症治疗中是一种很有前景的治疗方法,而在许多类型癌症的临床响应,包括前列腺癌(PCa)仍旧有限。肿瘤细胞通过外泌体或者剪接变异分泌PD-L1,并且在许多类

经典病例:高危前列腺癌新辅助新型内分泌治疗+前列腺癌根治术

57岁男性,因“查体发现前列腺特异抗原(PSA)升高5天”于门诊就诊,否认既往疾病史。

Sci Rep:MicroRNA-299-3p的多元功能促进了抗肿瘤微环境的形成

前列腺癌(PCa)是世界范围内影响男性健康最常见的癌症之一。雄激素受体(AR)信号是PCa和PCa治疗的核心部分。而MicroRNAs(miRNAs)通过调节信号途径在前列腺癌的调控中具有关键的作用。

Nat Commun:OXPHOS在高等级前列腺癌中的重构参与了mtDNA变异并增加琥珀酸氧化

能量代谢的重组和线粒体的适应被认为影响了前列腺癌的发展和恶化。最近,有研究人员报道了良性/恶性人类前列腺组织样本中,线粒体呼吸、DNA变异和基因表达的情况。